Development of a peptide-containing chewing gum as a sustained release antiplaque antimicrobial delivery system

AAPS PharmSciTech

Volumn 8, Issue 1, 2007, Pages

  Faraj, Jabar A ^a   Dorati, Rossella ^b   Schoubben, Aurélie ^c   Worthen, David ^a   Selmin, Francesca ^d   Capan, Yilmaz ^e   Leung, Kai ^f   DeLuca, Patrick P ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e HACETTEPE UNIVERSITY   (Turkey)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Antimicrobial; Antiplaque; Cetylpyridinium chloride; Chewing gum; KSL W; Peptide; Stability; Sustained release

Indexed keywords

ANTIINFECTIVE AGENT; CETYLPYRIDINIUM SALT; HYDROXYAPATITE; LYSYLLYSYLVALYLVALYLPHENYLALANYLLYSYLVALYLLYSYLPHENYLALANYLLYSINE; PEPTIDE DERIVATIVE; SERINE PROTEINASE; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; DRUG CARRIER; EXCIPIENT;

ACIDITY; AQUEOUS SOLUTION; ARTICLE; BACTERIAL GROWTH; CHEWING GUM; CONTROLLED STUDY; DENTAL CARIES; DRUG ABSORPTION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG STABILITY; GROWTH INHIBITION; HUMAN; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; MOUTH FLORA; PH; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SUSTAINED RELEASE FORMULATION; TEMPERATURE DEPENDENCE; TOOTH PLAQUE; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; DRUG FORMULATION; DRUG SCREENING; MATERIALS TESTING; METHODOLOGY; ORAL DRUG ADMINISTRATION; SALIVA;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CHEWING GUM; DELAYED-ACTION PREPARATIONS; DENTAL PLAQUE; DIFFUSION; DRUG CARRIERS; DRUG COMPOUNDING; DRUG EVALUATION, PRECLINICAL; EXCIPIENTS; HUMANS; MATERIALS TESTING; SALIVA;

EID: 34247221074     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt0801026     Document Type: Article

References (32)

1. Paster BJ, Otsen I, Aas JA, Dewhirst FE. The breadth of bacterial diversity in the human periodontal pocket and other oral sites. Periodontol 2000. 2006;42:80-87.
2. Aas JA, Pager BJ, Stokes LN, Olsen I, Dewhirst FE. Defining the normal bacterial oral cavity. J Clin Microbiol. 2005;43:5721-5732.
3. Marsh PD. Dental plaque as a biofilm and a microbial community: implications for health and disease. BMC Oral Health. 2006;6:S14.
4. Holt RL. Studies on human dental plaque. 1. Physical and chemical characteristics and enzyme activities of pooled plaque extracts. J Oral Pathol. 1975;4:73-85.
5. Scheie AA, Fejerskov O, Danielsen B. The effects of xylitol-containing chewing gums on dental plaque and acidogenic potential. Int Dent J. 1994;46:91-96.
6. Papanaou PN. Microbial markers of periodontal diseases. In: Busscher HJ, Evans LV, eds. Oral Biofilms and Plaque Controls. Amsterdam, The Netherlands: Harwood Academic Publishers; 1999:205-220.
7. Olsson J, van der Heijde Y, Holmberg K. Plaque formation in vivo and bacterial attachment in vitro on permanently hydrophobic and hydrophilic surfaces. Caries Res. 1992;26:428-433.
8. Gibbons RJ. Bacterial adhesion to oral tissues: a model for infectious diseases. J Dent Res. 1989;68:750-760.
9. Marsh PD. Microbial ecology of dental plaque and its significance in health and disease. Adv Dent Res. 1994;8:263-271.
10. Concannon SP, Crowe TD, Abercrombie JJ, et al. Susceptibility of oral bacteria to an antimicrobial decapeptide. J Med Microbiol. 2003;52:1083-1093.
11. Wilson M. Susceptibility of oral bacterial biofilms to antimicrobial agents. J Med Microbiol. 1996;44:79-87.
12. Leung KP, Crowe TD, Abercrombie JJ, et al. Control of oral biofilm formation by an antimicrobial decapeptide. J Dent Res. 2005;84: 1172-1177.
13. Na DH, Faraj J, Capan Y, Leung KP, DeLuca PP. Chewing gum of antimicrobial decapeptide (KSL) as a sustained antiplaque agent: preformulation study. J Control Release. 2005;107:122-130.
14. Na DH, Faraj J, Copan Y, Leung KP, DeLuca PP. Stability of antimicrobial decapeptide (KSL) and its analogues for delivery in the oral cavity. Pharm Res. In press.
15. Bonesvoll P, Lokken P, Rolla G, Paus PN. Retention of chlorhexidine in the human oral cavity after mouth rinses. Arch Oral Biol. 1974;19:209-212.
16. Ainamo J, Etemadzadeh H. Prevention of plaque growth with chewing gum containing chlorhexidine acetate. J Clin Periodontol. 1987;14:524-527.
17. Rassing MR. Chewing gum as a drug delivery system. Adv Drug Deliv Rev. 1994;13:89-121.
18. Jenssen ME, Lokind KB. Chewing gum as a drug delivery system: influence of additives upon the rate of release metronidazole and propranolol hydrochloride from chewing gum. Farin Sci Ed. 1988;16:94-97.
19. Yang X, Wang G, Zhang X. Release kinetics of catechines from chewing gum. J Pharm Sci. 2004;93:293-299.
20. Krook M, Lindbladh C, Erikson JA, Mosbach K. Selection of a cyclic nonapeptide inhibitor to α-chymotripsin using a phage display peptide library. Mol Divers. 1997;3:149-159.
21. Kvist C, Andersson SB, Fors S, Wennergren B, Berglund J. Apparatus for studying in vitro drug release from medicated chewing gums. Int J. Pharm. 1999;189:57-65.
22. Rassing MR. Specialized oral mucosal drug delivery systems: chewing gums. In: Rathbone MJ, ed. Oral Mucosal Drug Delivery. New York, NY. Marcel Dekker, 1996:319-357.
23. Rolla G, Loe H, Schiott CR. Affinity of chlorhexidine to hydroxyapatite and to salivary mucins. J Periodontal Res. 1970;5:90-95.
24. Rolla G, Loe H, Schiott CR. The retention of chlorhexidine in the human oral cavity. Arch Oral Biol. 1971;16:1109-1116.
25. Emilson CG, Erickson T, Hoyden G, Magnusson BC. Uptake of chlorhexidine to hydroxyapatite. J Periodontal Res. 1973;8:17-21.
26. Charles CH, Mostler KM, Bartels LL, Mankodi SM. Comparative anti-plaque and antigingivitis effectiveness of a chlorhexidine and an essential oil mouth rinse: 6-month clinical trial. J Clin Periodontol. 2004;31:878-884.
27. Ehara A, Torii M. Imazato S, Ebisu S. Antibacterial activities and release kinetics of a newly developed recoverable controlled agent-release system. J Dent Res. 2000;79:824-828.
28. Siewert M, Dressman J, Brown CK, Shah VP. FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech. 2003;4:Article 7.
29. Lif Holgerson P, Stecksen-Blicks C, Sjostrom I, Twetman S. Effect of xylitol-containing chewing gums on interdental plaque: pH in habitual xylitol consumers. Acta Odontol Scand. 2005;63:233-238.
30. Soderling E, Trahan L, Tammiala-Salonen T, Hakkinen L. Effect of xylitol, xylitol-sorbitol, and placebo chewing gums on the plaque of habitual xylitol consumers. Eur J Oral Sci. 1997;105: 170-177.
31. Humphrey SP, Williamson RT. A review of saliva: normal composition, flow, and function. J Prosthet Dent. 2001;85:162-169.
32. Herrera D, Santos S, Ferrus J, Barbieri G, Trombelli L, Sanz M. Efficacy of a 0.15% benzydamine hydrochloride and 0.05% cetylpyridinium chloride mouth rinse on 4-day de novo plaque formation. J Clin Periodontol. 2005;32:595-603.